First ALS Patient Enrolled in Phase 2b Study of NeuroSense’s PrimeC
A Phase 2b clinical trial evaluating NeuroSense Therapeutics’ experimental combination therapy PrimeC in people with amyotrophic lateral sclerosis (ALS)…
Articles by Margarida Maia, PhD
Target ALS Biomarker Study Open to Patients and Healthy Family, Friends
The Barrow Neurological Institute in Phoenix, Arizona, is calling on people with amyotrophic lateral sclerosis (ALS) and their…
Gene Therapy Lowers Toxic RNA Due to C9ORF72 Mutations in ALS
One-time delivery of a CRISPR-based gene therapy significantly reduced the buildup of toxic RNA molecules resulting from C9ORF72 mutations in…
Applications Are Being Accepted for Jane Calmes ALS Scholarship Fund
The Jane Calmes ALS Scholarship Fund wants to help support students who wish to pursue undergraduate studies, but whose…
NeuroSense Cleared to Study PrimeC Food Interactions in Healthy People
NeuroSense Therapeutics will soon begin a Phase 1 clinical trial to investigate the impact of food on PrimeC, a…
Lab Results Support Advancing QRL-201 to Clinical Trial
An investigational antisense oligonucleotide (ASO) molecule that works by increasing the production of Stathmin-2 protein effectively reversed a number of…
Stem Cell Therapy Safe, Shows Potential to Slow Progression in Trial
Repeat injections of mesenchymal stem cells (MSCs) into the spinal canal were safe and well tolerated in patients with…
TQS-168 Found to Reduce Inflammation, Extend Survival in Mice
TQS-168, an investigational therapy being developed by Tranquis Therapeutics, reduced inflammation in mouse and human models of amyotrophic…
Higher ‘Good’ Cholesterol Levels Appear to Lower Risk of ALS
Certain blood biomarkers of lipid, or fat, metabolism — typically measured to determine a person’s risk of cardiovascular disease —…
Speech Study Using AI Technology to Spot ALS Biomarkers
A technology based on artificial intelligence is helping to spot biomarkers and document the progression of amyotrophic lateral sclerosis…